The ketogenic diet does not slow growth of flank allograft tumors, and it does not affect tumor regression induced by GDC-0449.

<p>(A-C) Three distinct spontaneous medulloblastoma from <i>Ptch1</i>^{<b><i>+/-</i></b>}<i>Trp53</i>^{<b><i>-/-</i></b>} mice were used for these studies. Tumor volume differences were not statistically significant in two of the three trials. In the first trial, tumor volume was significantly lower at several time points (<i>p</i> = 0.001 to 0.048 on days 5 to 8; Student t-test). However, the difference was not evident when tumor volume was calculated as a percentage of total animal weight. Mice in all three trials lost approximately 9 to 13% of their body weight on the ketogenic diet whereas those on the standard diet maintained or marginally gained weight. (D) Glucose levels were significantly lower by day 7 (<i>p</i> = 0.027). (E) Ketone levels were significantly different between the standard and ketogenic diet groups (<i>p</i> = 0.0003 at 2 days; <i>p</i> = 0.013 at 7 days). (F) The ketogenic diet did not affect tumor regression induced by the SMO inhibitor GDC-0449. Tumor volumes regressed similarly on inhibitor treatment and had similar regrowth when removed from treatment.